Study Finds Presurgery Immunotherapy Safe for Patients with Pancreatic Cancer
Pancreatic cancer is a challenging cancer to treat. Research shows that roughly 12% of individuals diagnosed with this particular cancer live beyond five years. Additionally, treatments such as chemotherapy, immunotherapy and targeted therapies are unsuccessful in treating pancreatic cancer. Prior research has determined that combined PD1-inhibitors and chemotherapy hasn’t brought any improvements in pancreatic cancer patients. PD1-inhibitors are an immunotherapy drug that assists the immune system in recognizing and eliminating cancer cells effectively. Now, new research suggests that individuals with pancreatic cancer can undergo immunotherapy prior to surgery, with scientists noting that this may improve long-term outcomes. The research was…